Moderna Piotroski F Score

MRNA
 Stock
  

USD 142.85  0.04  0.028%   

This module uses fundamental data of Moderna to approximate its Piotroski F score. Moderna F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Moderna. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Moderna financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Additionally, see Moderna Altman Z Score, Moderna Correlation, Moderna Valuation, as well as analyze Moderna Alpha and Beta and Moderna Hype Analysis.
  
Refresh
Moderna Total Debt is projected to increase significantly based on the last few years of reporting. The past year's Total Debt was at 705 Million. The current year Debt Non Current is expected to grow to about 760.7 M, whereas Issuance Repayment of Debt Securities is forecasted to decline to (143.7 M). Moderna PPandE Turnover is projected to increase significantly based on the last few years of reporting. The past year's PPandE Turnover was at 24.02. The current year Accounts Payable Turnover is expected to grow to 124.42, whereas Long Term Debt to Equity is forecasted to decline to 0.0349.
At this time, it appears that Moderna's Piotroski F Score is Strong. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
7.0
Piotroski F Score - Strong
1
Current Return On AssetsPositiveFocus
2
Change in Return on AssetsIncreasedFocus
3
Cash Flow Return on AssetsPositiveFocus
4
Current Quality of Earnings (accrual)DecreasingFocus
5
Asset Turnover GrowthIncreaseFocus
6
Current Ratio ChangeIncreaseFocus
7
Long Term Debt Over Assets ChangeHigher LeverageFocus
8
Change In Outstending SharesDecreaseFocus
9
Change in Gross MarginIncreaseFocus

Moderna Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to Moderna is to make sure Moderna is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Moderna's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Moderna's financial numbers are properly reported.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares339.6 M403 M
Fairly Down
Increasing
Slightly volatile
Weighted Average Shares Diluted357 M431 M
Significantly Down
Increasing
Slightly volatile
Net Cash Flow from Operations14.7 B13.6 B
Significantly Up
Increasing
Slightly volatile
Total Assets26.6 B24.7 B
Significantly Up
Increasing
Slightly volatile
Total Liabilities11.4 B10.5 B
Significantly Up
Increasing
Slightly volatile
Current Assets17.3 B16.1 B
Significantly Up
Increasing
Slightly volatile
Current Liabilities9.8 B9.1 B
Significantly Up
Increasing
Slightly volatile
Total Debt760.7 M705 M
Significantly Up
Increasing
Slightly volatile
Return on Average Assets0.710.656
Significantly Up
Increasing
Slightly volatile
Gross Margin0.860.858
Slightly Up
Decreasing
Slightly volatile
Asset Turnover1.070.993
Significantly Up
Increasing
Slightly volatile

Moderna F Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Moderna's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Moderna in a much-optimized way.

About Moderna Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

Book Value per Share

37.87

Share
Moderna Book Value per Share is projected to increase significantly based on the last few years of reporting. The past year's Book Value per Share was at 35.10

Moderna Current Valuation Drivers

We derive many important indicators used in calculating different scores of Moderna from analyzing Moderna's financial statements. These drivers represent accounts that assess Moderna's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Moderna's important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(235.46 M)(359.55 M)(484 M)(651 M)13.52 B14.58 B
Earnings Before Interest Taxes and Depreciation Amortization USD(235.46 M)(359.55 M)(484 M)(651 M)13.52 B14.58 B
Earnings before Tax(256 M)(384.41 M)(515 M)(744 M)13.29 B14.33 B
Free Cash Flow(389.88 M)(436.63 M)(491 M)1.96 B13.34 B14.39 B
Invested Capital772.9 M1.11 B1.34 B531 M9.4 B10.14 B
Tangible Asset Value1.08 B1.96 B1.59 B7.34 B24.67 B26.62 B
Working Capital591.76 M1.34 B985.69 M1.91 B6.94 B7.49 B

About Moderna Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Moderna's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Moderna using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Moderna based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States and internationally. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Moderna operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2700 people.

Moderna Investors Sentiment

The influence of Moderna's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Moderna. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Moderna Implied Volatility

    
  90.95  
Moderna's implied volatility exposes the market's sentiment of Moderna stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Moderna's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Moderna stock will not fluctuate a lot when Moderna's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Moderna in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Moderna's short interest history, or implied volatility extrapolated from Moderna options trading.

Current Sentiment - MRNA

Moderna Investor Sentiment

Most of Macroaxis users are now bullish on Moderna. What is your trading attitude regarding investing in Moderna? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Moderna using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Moderna Altman Z Score, Moderna Correlation, Moderna Valuation, as well as analyze Moderna Alpha and Beta and Moderna Hype Analysis. Note that the Moderna information on this page should be used as a complementary analysis to other Moderna's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Complementary Tools for Moderna Stock analysis

When running Moderna price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Is Moderna's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
2.02
Market Capitalization
56.8 B
Quarterly Revenue Growth YOY
2.13
Return On Assets
0.5
Return On Equity
1.4
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine Moderna value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.